Amgen’s Phase 3 Aranesp trial in MDS meets primary endpoint
16 February 2016 | By Victoria White
Aranesp reduced the incidence of red blood cell transfusions in anaemic patients with low and intermediate-1 risk myelodysplastic syndrome...
List view / Grid view
News
Zepatier to threaten the dominance of Harvoni in the HCV market
15 February 2016 | By Victoria White
A GlobalData analyst says that the combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake...
Easy and quick HPLC analysis of Aflatoxin in milk
Aflatoxins are naturally occurring mycotoxins that are produced by different species of fungi. In addition to the most toxic aflatoxin B1, a number of other related compounds are occurring in nature. High level exposure to aflatoxins can, for example, produce acute hepatic necrosis especially children, whilst adults have higher tolerances.
Solar cell improvements reduce fossil fuel dependence
15 February 2016 | By Edinburgh Instruments
We are delighted to have accomplished installation of our top end fluorescence spectroscopy systems at the brand new Vidyasirimedhi Institute of Science and Technology (VISTEC) in Thailand...
Heart UK questions absence of lipidologists after NICE limits cholesterol-busting drug use
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
CMA fines pharmaceutical companies £45 million
12 February 2016 | By Victoria White
The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine...
ADHD drug Adzenys addresses unmet need for patients, says GlobalData
12 February 2016 | By Victoria White
The recent FDA approval of Adzenys will provide patients who have problems swallowing pills with easy-to-administer drug options, according to GlobalData analyst...
Vitamin D Level Determination in Serum
Vitamin D3 (cholecalciferol) is essential for the human body. Low levels of vitamin D3 increase the risk of illness from a range of disorders. Babies, young children, pregnant mothers and old people are at a higher risk.
Amgen’s Kyprolis launches in the UK for relapsed multiple myeloma
12 February 2016 | By Victoria White
Kyprolis (carfilzomib) is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma...
Sandoz acquires rights to biosimilar infliximab in the EEA
12 February 2016 | By Victoria White
Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
Quotient Clinical celebrates its 100th RapidFACT® program
11 February 2016 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues...
Incyte discontinues JANUS 1 study of ruxolitinib plus capecitabine
11 February 2016 | By Victoria White
Incyte has decided to discontinue the Phase 3 JANUS 1 study of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer.
Results from TITAN study of caplacizumab published
11 February 2016 | By Victoria White
Results from Ablynx’s worldwide Phase II TITAN study with caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) have been published...
Results from eribulin study in liposarcomas and leiomyosarcomas published
11 February 2016 | By Victoria White
Eisai's Halaven (eribulin) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action...
Alzheimer’s disease treatment market to more than double by 2021, says GBI Research
11 February 2016 | By Victoria White
GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period...
